A Fox got into the Cash Box: The Genetic Signatures Story (GSS)

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

I love a good boardroom battle.

And last week, the sparring began.

In the blue corner… Genetic Signatures (ASX: GSS) - a diagnostics play sitting on more cash than its market cap.

In the pink corner… BCAL Diagnostics (ASX: BDX) - a company that needs cash to ramp up commercial activities and is looking to bridge the gap.

BCAL just grabbed a 10% stake in GSS.

Uninvited.

GSS's response? 

"We weren't notified."

(Not exactly rolling out the welcome mat.)

I own 70,000 shares in GSS as a trading position, so I’ve been watching this one closely.

So, what’s the story?

… and more importantly, what happens next?

But first…

Syntara Limited (ASX: SNT) announces the results of its Phase 2 brain inflammation trial for iRBD, which leads to Parkinson’s Disease. (SNT, not held) 

🪑 Directionally positive without being a slam dunk on one of Syntara’s “side-bets”.

20 of 30 patients showed improvements in one of the key regions of the brain that were of interest, the putamen (with no significant change in the other three regions of interest). 

It will take someone much smarter than me to explain how important the putamen is to the degeneration of Alzheimer’s disease - the answer to that question will indicate how good these results are.

Cynata Therapeutics (ASX: CYP) announces the redundancy of all employees, including the CEO and Managing Director. (CYP, not held)

🪑 Translation: we are now a shell.

Immuron (ASX: IMC) engaged a consulting firm to licence out the development of its asset for Clostridioides difficile infection. (IMC, not held)

🪑 📢 Extra! Extra! Asset for sale.

Nyrada Inc (ASX: NYR) commences dosing in its Phase IIa trial of Xolatryp® to assess safety and efficacy in patients with heart attack, with top-line results expected by late 2027. (NYR, not held)

🪑 Off to the races!

CurveBeam AI Limited (ASX: CVB) has requested a trading halt pending an announcement about a capital raising. (CVB, not held)

Let’s go back to the beginning.

(Or at least the key inflection point)

In 2024, Genetic Signatures (ASX: GSS) raised $30 million following FDA clearance of its EasyScreen PCR test for Gastrointestinal Parasite Detection.

It was billed as the broadest FDA-cleared molecular parasite test on the market.

The thesis was simple… 

Capture a slice of an estimated 5.5 million-tests-a-year addressable market, with a CPT reimbursement code already in place at ~US$263/test.

A fancy new CEO was hired.

(She was the Managing Director of Roche Diagnostics in Australia).

Regal comes into the raise.

Perennial tips more in.

Asia Union Investments tips more in.

But as I’ve written about before with Diagnostics, getting FDA clearance is just the starting line… 

You still need to sell it!

The first sales came eight months after FDA clearance…

A long time for a company that was “immediately” set to begin commercialisation.

At the same time, the company started to pare back its innovation pipeline, pausing development of its Next Generation Instrument.

In presentations, the “cash balance” was a company highlight, and the sales progress on the EasyScreen in the US was few and far between.

Six months after first sales, the CFO resigns.

The CEO gets slapped with a ~50% pay cut…

This was late in 2025.

The Chairman’s address that year was markedly different from the 2024 celebrations from the FDA clearance.

Then the CEO resigns one month after the pay cut.

Emergency stations.

“Formal review process” begins in January. 

… and then the selling starts.

Indiscriminate selling from major shareholders begins.

Change in substantial shareholder notice.

Change in substantial shareholder notice.

Change in substantial shareholder notice.

… on and on.

It was relentless.

The board and cleanup crew did their best to review operations based on the results of the 90-day flash review… 

Cut costs, pause US spending, review product pipeline and target APAC/Europe.

This was all in the lead-up to the end of the financial year.

Tax loss season.

At 6.5 cents, the company traded at a market cap of ~$15 million, which is around $10 million under its cash backing.

What happens next is interesting.

There is a block trade of around ~10% (or 21 million shares) that goes live the day before the end of the financial year:

I had been watching the company like a hawk (as I owned a small trading position in it), so I flicked through a couple of messages to some broker friends to see who it could be.

I didn’t have to wait long to find out. 

It was announced the next morning that ANOTHER ASX-listed company, BCAL Diagnostics (ASX: BDX), had taken a 10% stake in the company.

I have done a deep-dive review of BCAL as part of my Biotech 165 Challenge, so I am familiar with the company.

Read: Climbing the Diagnostics Mount Everest, the BCAL Story (BDX)

Interestingly, days before the deal, BCAL secured another $4.9 million extension to its loan facility.

Now, BCAL is in an interesting position.

Ramping up commercial activities for its breast cancer test and various other in-licensed cancer tests in Australia.

It has a ~$15 million convertible note facility and 1.6 quarters of cash remaining, according to its most recent quarterly report.

Ramping up commercial activities isn’t cheap (in particular for a diagnostics product).

The goal is to get its products approved in the Australian Medical Benefit Scheme (according to the half-year presentation), which would help drive adoption.

This is still 6 to 12 months away, so to accelerate its commercialisation activities, BCAL has found a creative way to bridge the funding gap…

Genetic Signatures’ cash box.

Now, this is just speculation on my part… 

According to BCAL’s announcement, “the strategic rationale [for the investment]… is the potential to gain access to Genetic Signatures’ platform”.

But the narrative began to unravel when Genetic Signatures responded the next day, stating that “it was not notified” and had “no prior knowledge of the proposed acquisition of shares”.

The Genetic Signatures plan is clear.

The company presented the results of its 90-day review last month (I actually watched the whole presentation).

Pause US. Focus on Europe and APAC. Reduce costs. Reset the product portfolio.

… oh, and implement AI.

And they have said in their response announcement to BCAL’s share acquisition that they intend to stick to this plan.

With a greater-than-10% holding in the company, BCAL is in a position to 249D the board and put the control of the company to a shareholder vote.

There are still a number of funds on Genetic Signatures' books.

FIL, Mercer, Regal and Perennial.

Ultimately, THEY will be the ones that will decide the fate of the company:

Now, BCAL has briefly mentioned the synergies it sees between its company and Genetic Signatures.

…without going into much detail beyond that strategy.

I expect that over the coming weeks and months, we will see what BCAL’s plan is for Genetic Signatures.

An ASX-listed company doesn’t take an unsolicited 10% position in another ASX-listed peer without having a plan.

Merger? Strategic Partnership? 

… it’s all speculation for now.

But ultimately, it's the shareholders of the company that get to decide its fate.

For BCAL, they are in a strong position - they now have options to finance the company through to a potential key milestone of MBS inclusion next year.

For Genetic Signatures, it gets a bit tricky.

I’ve seen this play out before, with fighting over a cash box, with another ASX-listed company, Percheron (ASX: PER).

What happened there?

FIRST, Percheron raised capital: $13M raised in October of 2024, two months before top-line results were set to be announced for the company’s Phase IIb muscular dystrophy trial. (Announcement)

(For context, this drug had been in development for ~20ish years under the old company name of Antisense Therapeutics)

THEN, the topline results for the Phase IIb were published and “no statistical significance in efficacy” was found. (Announcement)

The stock price drops from $0.06 to $0.009 in one day.

… and then the sharks start to circle.

FIRST 249D, a board spill resolution from a number of existing shareholders. The asset had been in development for over 20 years, and they believed it may be worth salvaging, given the capital invested so far (The Antisense Faction). (Announcement)

A second faction (Power House Ventures) begins buying shares on the open market and seeks to become a substantial shareholder (>10%).

SECOND 249D, from Power House Ventures.

Eventually the board won BOTH 249D battles, but it was messy.

At the start, Percheron had $17 million in cash in the bank and ended the year with just ~$5 million and a new asset.

(A decent chunk went toward paying vendors for the trial and the asset acquisition).

I cover this in detail in my Percheron article here: The $12M Prize: How PER Survived Two Board Coups and Lived to Fight On 

So these “cash backing” plays CAN be tricky… particularly if the boardroom battles emerge.

There is opportunity here…

But the collateral damage tends to be the small shareholders of the cash box when the gods on Olympus (those large shareholders) decide what to do with the company.

See you all tomorrow,

The Armchair Analyst